NewsBenzingaVivos Therapeutics 将收购 SOD Sciences 11% 股权以及 SOD 专有“假缺氧”早期预警检测 50% 权益，交易对价为新设可转换优先股 1.2 万股，价值 1200 万美元 Vivos Therapeutics 将收购 SOD Sciences 11% 股权以及 SOD 专有“假缺氧”早期预警检测 50% 权益，交易对价为新设可转换优先股 1.2 万股，价值 1200 万美元 Benzinga 2026.10.15 12:48 (GMT+0) Open on Benzinga Other news US Stocks Pre-Market: Chip Stocks and Cloud Infrastructure Companies Generally Decline IRYS up over 33% in past 24 hours, LIT up over 7%, TIA and OP down over 8% NVIDIA CEO Jensen Huang: Regulation cannot prevent AI safety incidents Reported Earlier, Fresenius Medical Care Launches multiFiltratePRO In US After FDA Clearance, Expanding Continuous Kidney Replacement Therapy Options For Acute Kidney Injury Reported Earlier, Cognizant Agrees To Buy DyFlex Solutions, Strengthening SAP, AI And Enterprise Platform Capabilities In Australia And New Zealand; Terms Not Disclosed Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027
Reported Earlier, Fresenius Medical Care Launches multiFiltratePRO In US After FDA Clearance, Expanding Continuous Kidney Replacement Therapy Options For Acute Kidney Injury
Reported Earlier, Cognizant Agrees To Buy DyFlex Solutions, Strengthening SAP, AI And Enterprise Platform Capabilities In Australia And New Zealand; Terms Not Disclosed
Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027
